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Down syndrome (DS) is characterized by a marked reduction in the size of the brain 
and cerebellum. These changes play an important role in the motor alterations and 
cognitive disabilities observed in this condition. The Ts65Dn (TS) mouse, the most 
commonly used model of DS, reflects many DS phenotypes, including alterations in 
cerebellar morphology. One of the genes that is overexpressed in both individuals with 
DS and TS mice is DYRK1A/Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A), which has been implicated in the altered cerebellar structural and 
functional phenotypes observed in both populations. The aim of this study was to 
evaluate the effect of Dyrk1A on different alterations observed in the cerebellum of TS 
animals. TS mice were crossed with Dyrk1A +/- KO mice to obtain mice with a triplicate 
segment of Mmu16 that included Dyrk1A (TS +/+/+), mice with triplicate copies of the 
same genes that carried only two copies of Dyrk1A (TS +/+/-), euploid mice that 
expressed a normal dose of Dyrk1A (CO +/+) and CO animals with a single copy of 
Dyrk1A (CO +/-). Male mice were used for all experiments. The normalization of the 
Dyrk1A gene dosage did not rescue the reduced cerebellar volume. However, it 
increased the size of the granular and molecular layers, the densities of granular and 
Purkinje cells, and dendritic arborization. Furthermore, it improved the 
excitatory/inhibitory balance and walking pattern of TS +/+/- mice. These results 
support the hypothesis that Dyrk1A is involved in some of the structural and functional 
cerebellar phenotypes observed in the TS mouse model. 
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Highlights: 
Dyrk1A is implicated in cerebellar alterations in a model of Down syndrome. 
Normalization of the Dyrk1A dosage rescues granular and Purkinje cell densities in 
trisomic mice. 
Normalization of the Dyrk1A dosage rescues the size of the granular and molecular 
layers. 



















Down syndrome (DS) is characterized by several structural and functional 
abnormalities in the central nervous system, and a reduction in brain size is one of the 
most important characteristics of this condition. Additionally, an even greater reduction 
in cerebellar volume is observed in fetuses, newborns, children and adults with DS. In 
these individuals, both the total volume and the sizes of specific cerebellar cortical 
structures, such as the internal granule layer (IGL) and molecular layer (ML), are also 
markedly smaller (Aylward et al., 1997; Rotmensch et al., 1997; Baxter et al., 2000; 
Winter et al., 2000; Guidi et al., 2011). These morphological alterations are likely 
caused by a decrease in the densities of cerebellar granule cells (GC) and Purkinje 
cells (Baxter et al., 2000; Guidi et al., 2011). 
 
Traditionally, the cerebellum has been regarded as a key regulator of motor control and 
motor learning (Palay and Chan-Palay, 1982). Children and adults with DS display fine 
motor deficits that have been attributed to cerebellar dysfunction (Latash and Corcos, 
1991; Latash et al., 2002). However, based on accumulating evidence, the cerebellum 
is implicated in higher cognitive functions (Hilber et al., 1998; Petrosini et al., 1998; 
Rondi-Reig and Burguière, 2005; Galiano et al., 2013; Rochefort et al. 2013). Because 
cognitive disabilities are a major hallmark of DS, the altered neuroanatomy of the 
cerebellum in individuals with DS may also be partially responsible for the observed 
cognitive deficits.  
 
Several murine models of DS present similar abnormalities in the cerebellum, 
beginning at early postnatal ages. The Ts65Dn (TS) mouse carries a triplication of the 
distal end of Mmu16, extending from the Mrp139 to the Znf295 genes (Sturgeon and 
Gardiner, 2011). TS mice have a smaller cerebellum, vermis, GL and ML, and less 
dense GC and Purkinje cell populations (Baxter et al., 2000; Roper et al., 2006; Necchi 
et al., 2008; Contestabile et al., 2009). Other murine models of DS, such as the Ts1Cje 
mouse, which is caused by trisomy of the Mmu16 region from Sod1 to Znf295 (Sago et 
al., 1998), and the Tc1 model, in which all of Hsa21 is triplicated, also have a smaller 
cerebellum and a less dense GC population (Olson et al., 2004; O’Doherty et al., 
2005).  
 
Because different murine models of DS and individuals with DS share similar cerebellar 
anomalies, the triplication of this set of orthologous genes might be responsible for 
these phenotypes. Several candidate Hsa21 genes have been reported to play roles in 
brain development. One of these genes is DYRK1A (dual-specificity tyrosine-(Y)-

















functions during brain development and in adult brain physiology (Becker and Sipple, 
2011; Tejedor and Hämmerle, 2011). DYRK1A is important for normal brain growth in 
both mice and humans (Fotaki et al., 2002; Moeller et al., 2008; van Bon et al., 2011; 
Guedj et al., 2012). This gene is expressed at high levels in the cerebellum (Martí et 
al., 2003), and murine models with altered Dyrk1A expression exhibit altered motor 
abilities (Altafaj et al., 2001; Martínez de Lagrán et al., 2004; Fotaki et al., 2002, 2004; 
Souchet et al., 2014). 
 
The aim of this study was to evaluate the role of the Dyrk1A gene in the various 
morphological alterations that occur in the cerebellum of the TS model of DS. TS mice 
were crossed with Dyrk1A KO mice to obtain mice with a triplicated segment of Mmu16 
that included Dyrk1A (TS +/+/+), mice that were trisomic but carried only two copies of 
Dyrk1A (TS +/+/-), euploid (CO) mice that expressed a normal dose of Dyrk1A (CO 
+/+) and CO animals with a single copy of Dyrk1A (CO +/-). Cerebellar volume, sizes of 
the GL and ML, GC and Purkinje cell densities, dendritic arborization, and the walking 




















1. Experimental animals 
Mice were generated by repeatedly backcrossing B6EiC3Sn a/A-Ts(17<16>)65Dn (TS) 
females with C57BL/6Ei x C3H/HeSNJ (B6EiCSn) F1 hybrid males. The Robertsonian 
Chromosome Resource (The Jackson Laboratory, Bar Harbor, ME, USA) provided the 
parental generations, and animals were mated at the animal facilities of the University 
of Cantabria.  
TS females were crossed with Dyrk1A+/- heterozygous male mice on a mixed 
C57BL/6-129Ola genetic background (Fotaki et al., 2002) to obtain the following groups 
of mice: i) mice carrying a triplicated Mmu16 segment (TS +/+/+) extending from the 
Mrp139 gene to the Znf295 gene, which includes the Dyrk1A gene; ii) mice trisomic for 
all of these genes but diploid for Dyrk1A (TS +/+/-); iii) euploid (CO) mice with a normal 
Dyrk1A dosage (CO +/+) and iv) CO animals with a single copy of Dyrk1A (CO +/-). 
To determine trisomy, animals were karyotyped using real-time quantitative PCR 
(qPCR), as previously described (Liu et al., 2003). C3H/HeSnJ mice carry a recessive 
mutation that leads to retinal degeneration (Rd). Hence, all animals were genotyped 
using standard PCR to detect the Rd mutation (Bowes et al., 1993). Experiments were 
performed using wt/wt or Rd1/wt animals. The Dyrk1A +/- mice were genotyped using 
PCR, as previously described (Fotaki et al., 2002). 
Ninety-six male mice were used. Ten animals (6-10 months old) from each group were 
tested in the MRI studies, and fourteen mice (5-6 months old) in each group were used 
in the remaining experiments. Eight animals from each group were used to i) 
immunohistochemically visualize Purkinje cell arborization, ii) quantify GC and Purkinje 
cell densities, iii) determine the density of glutamatergic and GABAergic synapse 
markers, and iv) perform the footprint study. Six animals from each group were used 
for the western blot analysis of Dyrk1A protein levels. The researchers were blinded to 
the genotypes and karyotypes of the animals throughout the experiments.   
2. Western blot analysis  
Mice were euthanized by decapitation, and the cerebellum was dissected. Whole-
tissue lysates of the cerebellum were prepared using a previously described method 
(García-Cerro et al., 2014). The total protein content of each sample was determined 
using the method described by Lowry et al. (1951). An identical amount of total protein 
(50 µg) from each sample was loaded onto a 10% sodium dodecyl sulfate-

















(PVDF) membrane (Bio-Rad, Hercules, CA, USA) using a Mini Trans-Blot 
Electrophoresis Transfer Cell (Bio-Rad). The efficient transfer of proteins was 
confirmed by staining the PVDF membrane with Ponceau red (Sigma-Aldrich, St. 
Louis, MO, USA). Non-specific binding of antibodies was prevented by incubating the 
membranes with TBST buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.05% 
Tween 20) containing 3% bovine serum albumin (BSA). Blots were incubated with a 
mouse monoclonal anti-DYRK1A antibody (1:250; Abnova Corporation, Taipei, Taiwan, 
ROC) diluted in TBST containing 3% BSA overnight at 4 °C. After the membrane was 
extensively washed with TBST, it was incubated with a goat anti-mouse IRDye 800CW 
antibody (1:10,000; LI-COR Biotechnology, Lincoln, Nebraska, USA) for 1 h at room 
temperature. The resulting fluorescence was detected using a LI-COR ODYSSEY IR 
Imaging System V3.0 (LI-COR Biotechnology). Images were exported and saved as 
gray scale TIFF files (16 bit) to improve the contrast between signal and noise. The 
integrated optical density of the bands was subsequently determined using ImageJ NIH 
software (http://rsb.info.nih.gov/ij) and normalized to the background values. The 
relative variations between the bands among the four groups of experimental mice 
were calculated in the same experiment. Each individual sample was evaluated in at 
least three independent experiments. Values were within a linear range. Blots were 
reprobed using a mouse monoclonal anti-GAPDH antibody (6C5) (1:2,000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) to ensure equal loading. 
 
3. Cerebellar volume (MRI) 
Mice were euthanized and their brains were fixed using transcardial perfusion with 
saline followed by 4% paraformaldehyde.  
MRI studies were performed using a Biospec USR7/30 spectrometer (Bruker, Ettlingen, 
Germany) with a 7-Tesla 30-cm bore magnet equipped with a 12-cm gradient insert 
capable of switching 400 mT/m in 90 ms.  
A 40-mm birdcage 1H-resonator was used for RF transmission and reception. Imaging 
experiments were performed on extracted brains that were placed in 2-ml syringes 
filled with 1X PBS (phosphate-buffered saline) to avoid susceptibility effects at 
tissue/air interfaces. 
Following the automatic calibration of the system (i.e., pulse power, shim, and 
resonance frequency) and the acquisition of a multi-planar scout image (Gradient 
echo), which was used as a localizer to correctly position the imaging planes, 3D 

















enhancement) pulse sequence with the following parameters: the field of view (FOV), 
20 x 12 x 8.6 mm3, and image matrix, 200 x 120 x 86 points, yielding an isotropic pixel 
resolution of 0.100 x 0.100 x 0.100 mm3/pixel; effective bandwidth, 50 kHz, RARE 
factor, 12; effective echo time, 63 ms (TE = 10.5 ms); repetition time, 1700 ms and 
number or averages, 6. The total acquisition time was 2 h 26 minutes. Image post-
processing procedures and analyses were performed using ImageJ software. 
 
4. Histological and staining procedures 
Animals were deeply anesthetized with pentobarbital and transcardially perfused with 
saline followed by 4% paraformaldehyde in PBS. Subsequently, the brains were post-
fixed with the same fixative overnight at 4 °C, cryoprotected in 30% sucrose and frozen 
in dry ice. The brains were cut in the sagittal plane into 30-µm-thick (cryostat) free-
floating sections for immunolabeling of glutamatergic and GABAergic synapse markers. 
For the remaining experiments, 5-µm-thick sections were collected on microscope 
slides. Tissue sections were stored at -20 °C. 
In all immunohistochemical studies, appropriate minimal positive and negative controls 
were used to avoid inaccurate conclusions about false-positive or false-negative 
results. As negative controls for immunostaining, assays were performed using a 
similar protocol, with the exception that primary antibodies were omitted. For positive 
controls, the specificity of antibodies was previously validated by western blot 
experiments showing the recognition of specific bands corresponding to the proteins 
examined in our study. 
 
5. Propidium iodide and DAPI staining 
Tissue sections were incubated at room temperature, and the zone of interest was 
marked using a hydrophobic marker. Next, sections were washed with 1X PBS twice 
for 5 minutes each, treated with PBS-Tw (0.05%) for 5 minutes, dried and placed in a 
humid and dark chamber. Tissue sections were then incubated with DAPI (4’6-
diamidino-2-phenylindole), a cytochemical marker of DNA, in PBS for 12 minutes to 
stain cell nuclei. Next, sections were washed three times with PBS for 5 minutes each. 
Purkinje cells were counterstained with propidium iodide (PI, dilution 1:2,000) for 20 
minutes. Then, sections were washed with PBS and mounted with Vectashield anti-

















6. Area of the vermis, thickness of the GL and ML and length of the Purkinje cell 
layer 
We obtained optical micrographs of DAPI-stained sagittal sections of the cerebellar 
vermis using a 5x objective (Leica DM6000 M, Leica Microsystems, Wetzlar, Germany) 
to estimate the different areas and lengths of regions of interest. This microscope 
automatically created single panoramic images of the cerebellum from each animal 
with which the different morphometric calculations were performed. 
The mean thicknesses of the GL and the ML were calculated by dividing the length of 
each layer in a midline sagittal section by the total area of the layer. The Purkinje cell 
layer was included in the estimate of the thickness of the ML. Because a stereological 
technique was not used, changes in the parameters between groups are expressed as 
a percentage difference vs. the CO +/+ group, as previously described (Baxter et al., 
2000).  
7. Quantification of granule cell density 
Granule cells were counted in 5-μm-thick sections of the GL stained with DAPI. Six 
sagittal sections of the cerebellar vermis were serially collected on glass slides. GL 
micrographs were recorded using a fluorescence microscope (Zeiss Axioskop 2 plus) 
under a 62x oil objective. Cells were counted within a 5,000-μm2 area. Eight 
independent and non-overlapping fields were randomly selected along the length of 
folias IV, V, VI and VII in the cerebellum of each animal, and the number of GCs in 
each field were counted. The Abercrombie correction factor (Abercombrie, 1946) was 
used to correct the estimates by applying the following formula:  
P = A [M / (L + M)] 
where P is the final estimate of the cell number, A is the number of nuclei counted, M is 
the thickness of the section in μm, and L is the mean nuclear diameter (also in μm). 
Eight nuclei were randomly selected from each animal to estimate the nuclear 
diameter.  
8. Quantification of Purkinje cell density 
The total number of cells stained with PI in a complete midline sagittal section was 
counted and divided by the length of the Purkinje layer for each animal to determine 



















9. Purkinje cell arborization 
We used calbindin immunohistochemistry to evaluate the dendritic arborization in 
Purkinje cells in the ML of the cerebellum. Briefly, 5-μm-thick sections of the vermis 
were collected from animals in each experimental group and placed on SuperFrost 
Plus microscope slides (ThermoFisher Scientific), washed with PBS (3 x 10 minutes) 
and incubated with blocking agent (5% fetal bovine serum and 0.1% Triton X-100 in 
PBS) for 1 h at RT. Then, tissue sections were incubated with the primary rabbit 
polyclonal anti-calbindin antibodies (Swant, Switzerland 1:7,000 in the blocking agent) 
overnight at 4 °C, washed with 0.05% Tween 20 in PBS, incubated with the anti-rabbit 
secondary antibodies (conjugated to Alexa Fluor 488, Life Technologies, 1:75) for 1 h 
at RT, washed with PBS, and mounted with Vectashield-DAPI anti-fade medium 
(Vector Laboratories). 
For each animal, a minimum of three regions of the ML of the cerebellar vermis were 
recorded using a Leica SP5 confocal microscope (Leica Microsystem, Wetzlar, 
Germany) with a 40x objective. Purkinje cell arborization was quantified using a 
systematic random design of dissector counting frames (100 x 100 µm2). Three 
independent fields were randomly selected along the cerebellar vermis. The intensity of 
calbindin immunoreactivity was measured using ImageJ software. First, images 
obtained under the microscope were transformed to 16-bit images and calibrated, and 
background staining was then subtracted. Later, images were transformed to 32-bit 
images and normalized to obtain a gray scale value within the range of 0 to 1, where 0 
represents white and 1 represents black. The mean gray values were measured within 
each frame and averaged to calculate the density for each animal.  
10. Density of glutamatergic and GABAergic synapse markers (VGluT1 and 
VGAT immunofluorescence, respectively)  
Free-floating, 30-µm sections of the cerebellar vermis were used to determine the 
density of GABAergic and glutamatergic synapse markers. Sections were first 
incubated with PBTBSA, and double immunohistochemistry was then performed. 
Glutamatergic and GABAergic boutons were immunolabeled using a guinea pig anti-
vesicular glutamate transporter 1 antibody (VGluT1, 1:2,500; Millipore, Billerica, MA, 
USA) and an anti-GABA vesicular transporter antibody (VGAT, 1:100; Santa Cruz 
Biotechnology, Dallas, TX, USA), respectively. Then, tissue sections were incubated 
with the following secondary antibodies: Alexa Fluor 488-conjugated goat anti-guinea 
pig (1:1,000; Invitrogen, Carlsbad, CA, USA) and Alexa Fluor 594-conjugated donkey 

















Immunolabeled synaptic boutons were measured in images obtained under a confocal 
microscope (Leica SP5). Four sections per animal were used to measure each 
synapse marker, and one random cerebellar area per section was measured. Images 
were analyzed using ImageJ software, as previously described (Martínez-Cué et al., 
2013). Briefly, boutons positive for either VGluT1 or VGAT (because these markers are 
never co-localized) were measured separately. The same threshold was applied to all 
images. Images were converted to grey scale to improve the contrast between signal 
and noise. The area inside of a reference circle with a standard size of 325 μm2 was 
measured. The reference space was located in the inner ML next to the Purkinje cell 
layer. The percentage of the reference area that was occupied by VGluT1- and VGAT-
positive boutons and the excitatory-inhibitory ratio (VGluT1/VGAT) were calculated. 
11. Footprint analysis  
Footprint tests were used to evaluate the walking patterns of the different groups of 
mice, according to the protocol described by Martínez de Lagrán et al. (2004). Black 
waterproof ink was applied to the hind paws of each individual mouse. The animals 
were then placed at one end of a long, narrow tunnel (10 cm x 10 cm x 70 cm), which 
they spontaneously entered. A clean sheet of white paper (50 cm) was placed on the 
floor of the tunnel to record their footprints. Footprints located in the first and last 15 cm 
of the sheet were excluded from the analysis to discard possible artifacts that are 
unrelated to motor behavior. Each animal repeated the task three times, resulting in 
clear footprints on 20 cm of sheet. The average length and width between the paw 
prints and the number of strides per trial were measured. The coefficient of variation 
was calculated as the ratio between the standard deviation and the mean value of five 
consecutive strides with the left paw. 
12. Experimental design and statistical analysis 
All data were analyzed using a two-way (‘karyotype’ x ‘Dyrk1A’) ANOVA. The mean 
values for each experimental group were compared using Bonferroni’s post hoc tests 
when all groups were compared and Student’s t-test when two groups were compared. 





















1. Levels of the Dyrk1A protein in the cerebellum are correlated with the dose of 
the Dyrk1A gene 
First, we determined the levels of the Dyrk1A protein in the cerebellum of each 
experimental group to evaluate whether its expression levels correlated with the 
Dyrk1A gene dosage. As expected, a western blot analysis of cerebellar lysates 
revealed a direct correlation between Dyrk1A protein levels and the number of Dyrk1A 
gene copies the animal carried. Thus, TS +/+/+ animals had higher levels of this 
protein than the CO +/+ mice (ANOVA ‘karyotype’: F(1,20) = 22.73, p < 0.001; figure 1). 
When the number of functional copies of Dyrk1A was reduced by one, the levels of this 
protein were normalized in TS +/+/- animals and reduced in CO +/- animals (‘Dyrk1A’: 
F(1,20) = 11.92, p = 0.003; ‘karyotype x Dyrk1A’: F(1,20) = 0.61, p = 0.44; figure 1). 
2. Knockout of one copy of the Dyrk1A gene reduced the cerebellar volume of 
CO +/- mice, but not of TS +/+/- mice 
When the effect of ‘karyotype’ on cerebellar volume was analyzed, we did not observe 
significant differences between the two groups of TS mice and the two groups of CO 
mice (ANOVA ‘karyotype’: F(1,36) = 3.01, p = 0.092). However, this finding was probably 
because although the CO +/- mice had a lower cerebellar volume (ANOVA ‘Dyrk1A’: 
F(1,36) = 12.86, p < 0.001) than the TS +/+/+ mice (TS +/+/+ vs. CO +/+, t = 7.26, p < 
0.001; figure 2). In fact, knockout of a functional copy of the Dyrk1A gene reduced the 
cerebellar volume of the CO +/- mice, but had no effect on the TS +/+/- animals 
(ANOVA ‘karyotype x Dyrk1A’: F(1,36) = 42.86, p < 0.001). 
3. Reducing the Dyrk1A gene dosage normalized the size of the cerebellar vermis 
in TS +/+/- mice  
TS +/+/+ mice presented a marked reduction in cerebellar size (12.9% smaller than the 
CO +/+ mice, figure 3), but the normalization of the Dyrk1A dosage completely 
rescued this alteration, as shown in the TS +/+/- mice, in which the cerebellar size was 
similar to the CO +/+ group (MANOVA ‘karyotype’ F(1,28) = 0.02, p = 0.889; ‘Dyrk1A’ 
F(1,28) = 0.155. p = 0.697; ‘karyotype x Dyrk1A’ F(1,28) = 3.877, p = 0.007; figure 3). In the 
CO +/- group, knockout of a functional copy of the Dyrk1A gene substantially reduced 

















4. The sizes of the GL and the ML were normalized after the number of functional 
copies of the Dyrk1A gene was reduced in TS +/+/- mice 
The thicknesses of the GL and ML were assessed to determine the mechanisms that 
contributed to the marked reduction in the area of the cerebellar vermis in TS +/+/+ 
mice and its recovery in TS +/+/- mice. The GL and ML were 11.8% and 16.8% 
smaller, respectively, in the TS +/+/+ mice than in the CO +/+ animals (figures 4A-4C). 
In addition, the cytoarchitecture of both layers was more organized in the TS +/+/- 
animals, in which the GL was 7.6% larger and the ML 9.6% larger than in the TS +/+/+ 
mice. Although these effects did not reach statistical significance (GL: ANOVA 
‘karyotype’: F(1,28) = 0.67, p = 0.67; ‘Dyrk1A’: F(1,28) = 0.41, p = 0.52; ‘karyotype x 
Dyrk1A’: F(1,28) = 7.27, p = 0.012; ML: ANOVA ‘karyotype’: F(1,28) = 0.70, p = 0.40; 
‘Dyrk1A’: F(1,28) = 2.44, p = 0.13; ‘karyotype x Dyrk1A’: F(1,28) = 22.94, p < 0.001), the 
sizes of the layers in the TS +/+/- mice were not different from the euploid mice.   
Consistent with the reduced cerebellar size observed in CO +/- mice, the GL was 
12.5% thinner and the ML was 18.9% thinner in this group than in the CO +/+ group 
(figures 4A-4C). Based on these results, Dyrk1A also plays a role in cerebellar 
development, and the normalization of its gene dosage in TS +/+/- mice contributed to 
improving the cerebellar phenotype, particularly in the ML. 
5. The Dyrk1A copy number affects the density of GCs and Purkinje cells in the 
cerebellum  
The cell density of the GL was analyzed to determine whether the partial recovery in 
the thickness of the GL observed in TS +/+/- mice was caused by an increase in the 
number of GCs or by changes in cellular packing. As shown in figures 5A and 5B, TS 
+/+/+ mice displayed a markedly lower GC density (p < 0.001). In the TS +/+/- mice, 
knockout of a copy of the Dyrk1A gene produced a nearly complete recovery of the GC 
density. In addition, the CO +/- mice displayed a substantial increase in GC density 
compared with that of the CO +/+ group (ANOVA ‘karyotype’: F(1,28) = 100.582, p < 
0.001; ‘Dyrk1A’: F(1,28) = 55.634, p < 0.001; ‘karyotype x Dyrk1A’: F(1,28) = 0.044, p = 
0.835). 
 
A lower linear density of Purkinje cells was observed in the TS +/+/+ than in the CO +/+ 
mice (figure 6, ANOVA ‘karyotype’: F(1,28) = 2.982, p = 0.096). This deficit disappeared 
after the dosage of the Dyrk1A gene was normalized in TS +/+/- mice. However, the 
reduction in the number of functional copies of this gene in the CO +/- mice did not 

















p = 0.059; ‘karyotype x Dyrk1A’: F(1,28) = 4.511, p = 0.043). In contrast to GCs, Purkinje 
cell numbers were not affected in mice displaying a reduced cerebellar size.  
6. Normalizing the dosage of the Dyrk1A gene restores Purkinje cell dendritic 
arborization in TS mice 
TS +/+/+ mice displayed lower levels of Purkinje cell dendritic arborization than their 
CO +/+ littermates (ANOVA ‘karyotype’: F(1,28) = 0.046; figure 7). However, the 
reduction in the number of copies of the Dyrk1A gene rescued this altered phenotype in 
TS +/+/- mice (ANOVA ‘Dyrk1A’: F(1,28) = 4.49, p = 0.044, figure 7), but did not have 
any effect on CO +/- mice (ANOVA ‘karyotype x Dyrk1A’: F(1,28) = 3.00, p = 0.095).  
7. Inactivating a copy of the Dyrk1A gene reduces the density of markers of 
inhibitory synapses and normalizes the density of markers of excitatory 
synapses in TS mice 
TS mice with two or three functional copies of the Dyrk1A gene displayed an increased 
density of inhibitory synapses (karyotype’: F(1,28) = 5.81, p = 0.023; figures 8A and 8B). 
However, knockout of the Dyrk1A gene had opposite effects on TS and CO mice, as it 
reduced the density of VGAT-positive boutons in TS mice but increased this value in 
CO +/- animals (ANOVA ‘Dyrk1A’: F(1,28) = 0.07, p = 0.78; ‘karyotype x Dyrk1A’: F(1,28) = 
87.83, p < 0.001; figures 8A and 8B). 
In addition, the density of excitatory synapses was markedly reduced in TS +/+/+ mice 
(ANOVA ‘karyotype’: F(1,28) = 30.61, p < 0.001; figures 8A and 8C). The reduction in 
the number of copies of the Dyrk1A gene in TS +/+/- and CO +/- animals increased the 
area occupied by VGluT1-positive boutons in both groups of mice (‘Dyrk1A’: F(1,28) = 
16.55, p < 0.001; ‘karyotype x Dyrk1A’: F(1,28) = 1.26, p = 0.27; figures 8A and 8C). 
When the ratio of excitatory/inhibitory synapse markers was calculated, a marked over-
inhibition was observed in the TS +/+/+ mice (ANOVA ‘karyotype’: F(1,28) = 12.26, p = 
0.002; figures 8A and 8D) that was partially compensated for in the TS +/+/- animals. 
However, CO +/- mice presented a marked reduction in the ratio of excitatory/inhibitory 
synapse markers because they exhibited a larger increase in the area occupied by 
VGAT-positive boutons than the area occupied by VGluT1-positive boutons (ANOVA 
‘Dyrk1A’: F(1,28) = 0.39, p = 0.53; ‘karyotype x Dyrk1A’: F(1,28) = 15.94, p < 0.001; figures 
8A and 8D). Thus, knocking out Dyrk1A partially restored the excitatory/inhibitory 
balance in TS +/+/- mice, but not in CO +/- animals. 
8. Normalizing the Dyrk1A gene copy number ameliorates the altered walking 

















TS +/+/+ mice displayed an abnormal walking pattern, with a shorter stride length 
(ANOVA ‘karyotype’: F(1,28) = 5.22, p = 0.037; figure 9A) and width (F(1,28) = 4.28, p = 
0.05; figure 9B), as well as a greater number of strides (F(1,28) = 10.77, p = 0.005; 
figure 9D).  
When the number of copies of the Dyrk1A gene was reduced by one, these deficits 
were ameliorated in TS +/+/- mice, but no effect was observed on CO +/- animals. The 
TS +/+/- group displayed a normalized stride length (‘Dyrk1A’: F(1,28) = 0.04, p = 0.83; 
‘karyotype x Dyrk1A’: F(1,28) = 11.62, p = 0.004; figure 9B) and stride number (F(1,28) = 
0.82, p = 0.38; ‘karyotype x Dyrk1A’: F(1,28) = 8.65, p = 0.011; figure 9D) that were 
similar to the values observed in CO +/+ animals. In addition, when the coefficient of 
variation was calculated, TS +/+/+ mice, but not TS +/+/- mice, displayed a more 
irregular walking pattern (ANOVA ‘karyotype’: F(1,28) = 0.001, p = 0.97; ‘Dyrk1A’: F(1,28) = 
0.009, p = 0.92; ‘karyotype x Dyrk1A’: F(1,28) = 9.44, p = 0.008; figure 9C). However, 
normalization of the Dyrk1A gene copy number did not have a significant effect on the 
stride width of the TS +/+/- animals (‘Dyrk1A’: F(1,28) = 0.00, p = 0.98; ‘karyotype x 
Dyrk1A’: F(1,28) = 3.17, p = 0.095; figure 9B). These results suggest that, although 
Dyrk1A overexpression might be implicated in these deficits, other factors must also 




















The results of this study provide support for the hypothesis that Dyrk1A plays a role in 
the altered morphology of the cerebellum in a mouse model of DS. As previously 
demonstrated, TS +/+/+ mice possess i) a smaller cerebellar volume, ii) vermis, GL and 
ML sizes, in addition to iii) a reduced density of GCs and Purkinje cells. Moreover, in 
TS +/+/+ mice, Purkinje cells exhibit abnormal dendritic arborization, imbalanced 
expression of excitatory and inhibitory synaptic markers and an abnormal gait pattern. 
When the number of functional copies of the Dyrk1A gene was reduced (TS +/+/- 
mice), the cerebellar volume was not modified, but the sizes of the vermis, GL and ML, 
the density of GCs and the density and arborization of Purkinje cells were normalized, 
and the excitatory-inhibitory balance and abnormal walking pattern were improved. 
First, high-resolution MRI revealed a reduction in the cerebellar volume in the TS +/+/+ 
mice than in their euploid littermates (CO +/+ mice). In addition, TS +/+/+ mice 
possessed a smaller cerebellar vermis, GL and ML, potentially because of changes in 
cell density or packaging. The results of the quantitative analysis showed reductions in 
the density of both GCs and Purkinje cells in TS +/+/+ mice. These results confirm 
those of previous studies showing marked reductions in cerebellar volume, the sizes of 
the vermis, GL and ML, and the densities of GCs and Purkinje cells in both murine 
models of DS and individuals with DS because of reductions in both the number of GC 
precursors and the rate of proliferation (Aylward et al., 1987; Rotmensch et al., 1997; 
Baxter et al., 2000; Winter et al., 2000; Olson et al., 2004; O’Doherty et al., 2005; 
Roper et al., 2006; Contestabile et al., 2009; Guidi et al., 2011). 
 
Regarding cerebellar volume, knockout of a functional copy of the Dyrk1A gene 
reduced the cerebellar volume in CO +/- mice, but did not have any effect on TS +/+/- 
animals. Dyrk1A +/- haploinsufficient mice (i.e., CO +/- mice) also display smaller 
brains and reductions in the sizes of different CNS regions (Fotaki et al., 2002). 
Because of the roles of DYRK1A/Dyrk1A in normal brain growth in humans and mice 
are well established (Fotaki et al., 2002; Moeller et al., 2008; van Bon et al., 2011; 
Guedj et al., 2012), we predicted that normalization of its gene dosage (TS +/+/- 
animals) would rescue the cerebellar volume. However, these animals presented a 
smaller cerebellar volume than the CO +/+ mice and were not different from TS +/+/+ 
mice. Thus, the loss of a copy of the Dyrk1A gene in CO +/- mice significantly reduced 
their cerebellar volume, whereas normalization of the gene dosage in TS +/+/- mice did 
not modify this parameter. In these animals, the abnormal expression of other genes 

















this sense, mice that do not exhibit altered Dyrk1A expression but carry extra copies of 
the SETD4, CBR1, CBR3, DOPEY2, MORC3, CHAF1B and CLDN14 genes (i.e., the 
203E8-YAC mouse) display altered cerebellar morphogenesis (Rachidi et al., 2007). 
Thus, Dyrk1A overexpression seems to play a role but does not fully account for the 
changes in cerebellar morphology observed in TS +/+/+ mice.  
Because the normalization of the Dyrk1A gene dosage in TS +/+/- animals rescued the 
size of the zones of the cerebellar cortex that were analyzed in this study (see below), 
Dyrk1A may play a role in the growth of some but not all cerebellar regions, such as 
the deep cerebellar nuclei, which were not evaluated in the present study. The 
development of the murine cerebellum is orchestrated by the interaction of multiple 
signaling pathways, which control the proliferation, migration and differentiation of 
neuronal and glial cell types. The neurogenesis of the vermis, a new evolutionary 
structure of mammals that is absent in other vertebrates, depends on FGF8, but the 
development of cerebellar lobes/hemispheres does not (Butts et al., 2014). In addition, 
the neuroepithelium of the IV ventricle generates all GABAergic neurons under control 
of the NOTCH1 and PTF1a pathway, whereas the rhombic lip, which is regulated by 
BMP/LMX1a signaling, is the source of glutamatergic neurons of cerebellar nuclei 
(Wriend et al., 2015). These pathways might be differentially affected by some of the 
genes overexpressed in TS +/+/+ mice, including Dyrk1A, leading to variations in the 
morphology and function of the different cerebellar structures.  
 
The reduction in the functional copy number of the Dyrk1A gene normalized the sizes 
of the vermis, GL and ML in TS +/+/- mice and reduced their sizes in CO +/- mice. In 
addition, TS +/+/- mice exhibited normal GC and Purkinje cell densities. However, 
although the densities of some neural populations are reduced in Dyrk1A +/- 
haploinsufficient mice (Fotaki et al., 2002), GC and Purkinje cell densities were not 
affected in CO +/- animals. Thus, the reduced size of different cerebellar zones 
observed in this group of mice was not accompanied by changes in cellular packaging.  
 
Both the density and the morphology of Purkinje cells were altered in TS +/+/+ mice. 
Consistent with the abnormal dendritic arborization observed in this neuronal 
population in the present study, Necchi et al. (2008) described morphological 
abnormalities in the axons of Purkinje cells. In the present study, the reduction in the 
functional copy number of the Dyrk1A gene rescued the dendritic arborization defect in 


















Therefore, although Dyrk1A seems to play a role in altering cerebellar morphology in 
TS mice, it is not the sole effector of this phenotype, and interactions between this 
gene and other genes or gene products, as well as differences in epigenetic 
modifications, may also contribute to some of the cerebellar alterations observed in 
these mice. Other genes that are triplicated in the TS mouse might play a role in the 
reduction in GC and Purkinje cell densities and the abnormal dendritic configuration 
observed in Purkinje cells. These genes include Pcp4, which encodes a protein 
expressed in Purkinje cells (PEP19) (Cabin et al., 1996; Créau et al., 2016); SETD4, 
CBR1, CBR3, DOPEY2, MORC3, CHAF1B and CLDN14, which play roles in cerebellar 
morphogenesis (Rachidi et al., 2007); and App, which is implicated in Purkinje cell 
differentiation (Ohta et al., 1993). Moreover, the Hsa21 orthologous genes that are 
triplicated in the TS mouse induce the aberrant expression of numerous non-Hsa21 
mRNA transcripts (Saran et al., 2003). Hence, the absence of normal molecular 
interactions in CO +/- mice might be responsible for the different effects on cerebellar 
morphology observed when the copy number of the Dyrk1A gene was reduced by one 
in TS +/+/- and CO +/- mice.  
 
The brains of TS mice are characterized by an imbalance between excitatory and 
inhibitory transmission (see Martínez-Cué et al., 2014). In the present study, the area 
of the cerebellum that expressed a marker of inhibitory synapses (VGAT) was larger 
and the area that expressed a marker of excitatory synapses (VGluT1) was smaller in 
TS +/+/+ mice. Dyrk1A has been reported to contribute to this imbalance. In mice with 
a higher dosage of Dyrk1A, inhibitory synapse markers occupy a larger area and 
excitatory synapse markers occupy a smaller area in various areas of the brain and 
cerebellum (García-Cerro et al., 2014; Souchet et al., 2014; 2015). In support of these 
findings, the reduction in the copy number of Dyrk1A (TS +/+/- mice) normalized the 
areas in the cerebellum occupied by both inhibitory and excitatory boutons. A recent 
study provided further support for the hypothesis that Dyrk1A plays a hyperinhibitory 
role in several areas of the brain (Souchet et al., 2015). The administration of Pol60, an 
extract containing the DYRK1A inhibitor epigallocatechin gallate (EGCG), restores 
components of excitatory/inhibitory balance in the cortex and hippocampus, but not the 
cerebellum, of Ts65Dn and mBACtgDyrk1a mice. The authors hypothesize that the 
lack of effects on this structure might be due to a reduced accessibility of the drug or to 



















Although Dyrk1A appears to contribute to the excitatory/inhibitory imbalance observed 
in TS +/+/+ animals, other genes, such as Synj1 (Voronov et al., 2008), Olig1 and Olig2 
(Chakrabarti et al., 2010), have been shown to play important roles in this phenotype.  
 
Finally, fine motor control is perturbed in individuals with DS (Latash and Corcos, 1991; 
Latash et al., 2002), and motor alterations are well established in some mouse models 
of DS that overexpress Dyrk1A (Altafaj et al., 2001). However, controversy exists 
regarding whether TS animals present altered motor activity. Some studies have 
observed altered motor coordination in TS mice (Costa et al., 1999; Gutierrez-
Castellanos, 2013), whereas others have reported normal (Escorihuela et al., 1998; 
Baxter et al., 2000) or improved (Hyde et al., 2001) motor coordination. In the present 
study, we performed a more demanding version of the rotarod test (data not shown) 
described by Costa et al. (1999), but we did not observe any differences in motor 
coordination between TS +/+/+ animals and any of the other groups of mice.  
 
However, deficits have been reported in the basic gait of TS +/+/+ animals (Costa et 
al., 1999). In the present study, these animals displayed an abnormal walking pattern 
that was characterized by a shorter stride length and width and a larger number of 
strides. The reduction in the copy number of the Dyrk1A gene (TS +/+/- mice) 
ameliorated these deficits but did not have a similar effect on CO +/- animals, 
suggesting that the structural benefits produced by normalizing the copy number of the 
Dyrk1A gene in TS mice may be partially responsible for these motor improvements.  
 
Based on accumulating evidence, the cerebellum is involved in higher cognitive 
functions, including procedural learning in spatial tasks (Rondi-Reig and Burguière, 
2005; Galiano et al., 2013; Rochefort et al., 2013). TS +/+/+ mice and transgenic 
Dyrk1A-overexpressing mice exhibit severe impairments in these cognitive domains 
(Smith et al., 1997; Altafaj et al., 2001; Ahn et al., 2006; Bartesaghi et al., 2011). 
Pharmacological manipulations that normalize cerebellar morphology in TS +/+/+ mice 
improve spatial learning and memory (Das et al. 2013), suggesting that the cerebellar 
hypoplasia observed in trisomic animals may contribute to some of their cognitive 
deficits. 
 
In summary, the Dyrk1A gene is involved in several of the morphological and functional 
cerebellar phenotypes observed in TS mice. However, normalization of the Dyrk1A 

















the altered walking pattern observed in these mice, suggesting that other genes or 
gene products are implicated in these cerebellar anomalies.  
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Figure 1. Normalization of the copy number of the Dyrk1A gene reduced levels of 
the Dyrk1A protein in the cerebellum of TS and CO mice. Representative images 
and western blot analysis of the levels of the Dyrk1A protein in the cerebellum of CO 
+/+, CO +/-, TS +/+/+ and TS +/+/- mice. Differences between CO +/-, TS +/+/+ and 
+/+/- animals are expressed relative to the values observed in CO (+/+) mice (defined 
as 100%) (B). GAPDH was used as an internal loading control. **: p < 0.01 TS +/+/+ 
vs. CO +/+; #: p < 0.01 TS +/+/+ vs. TS +/+/- or CO +/+ vs. CO +/- (n = 24 in B). 
Significance was determined using ANOVAs and Bonferroni’s post hoc test. 
Figure 2. Normalization of the Dyrk1A gene dosage did not rescue the reduced 
cerebellar volume observed in TS +/+/- mice. Representative MRIs of the horizontal, 
sagittal and coronal planes of the four groups of mice. The scale bar corresponds to 1 
mm (A). Means ± S.E.M. of the percentage differences in the cerebellar volume 
between TS +/+/+, TS +/- and CO +/- mice and CO +/+ mice (100%) (B). ***: p < 0.001 
TS +/+/+ vs. CO +/+ Student’s t-test; ###: p < 0.001 CO +/- vs. CO +/+ (n = 40 in B). 
Significance was determined using ANOVAs and Bonferroni’s post hoc test. 
Figure 3. Normalization of the Dyrk1A gene dosage rescued the size of the 
cerebellar vermis in TS +/+/- mice. Representative photographs of the cerebellar 
vermis of the four groups of mice. Tissues were stained with DAPI. The scale bar 
corresponds to 200 µm (A). Means ± S.E.M. of the percentage differences in the sizes 
of the cerebellar vermis between each experimental group and the CO +/+ group 
(100%) (B). **: p < 0.01, TS +/+/+ vs. CO +/+; #: p < 0.05, CO +/+ vs. CO +/- (n = 32 in 
B). Significance was determined using ANOVAs and Bonferroni’s post hoc test. 
Figure 4. Normalization of the Dyrk1A gene dosage partially restored the 
cerebellar architecture in TS +/+/- mice. Representative images of sections of the GL 
and ML, which are separated by the Purkinje cell layer (PL), in the four groups of 
animals. Sections were stained using DAPI. The white dotted line indicates the end of 
the ML. The scale bar corresponds to 50 µm (A). Means ± S.E.M. of the percentage 
differences in the thickness of the GL (B) and ML (C) compared to those of CO +/+ 
mice. **: p < 0.01, ***: p < 0.001 TS +/+/+ vs. CO +/+; ##: p < 0.01, ###: p < 0.001, CO 
+/+ vs. CO +/- (n = 32 in B and C). Significance was determined ANOVAs and 
Bonferroni’s post hoc test. 
Figure 5. Normalization of the Dyrk1A gene dosage restored the density of GCs 
in TS mice. Representative images of GCs stained with DAPI. The scale bar 
corresponds to 10 µm (A). Means ± S.E.M. of the estimated densities of GCs in each 
group (B). ***: p < 0.001, TS +/+/+ vs. CO +/+; ###: p < 0.001, CO +/+ vs. CO +/- and 
TS +/+/+ vs. TS +/+/- (n = 32 in B). Significance was determined using ANOVAs and 
Bonferroni’s post hoc test.  
Figure 6. Normalization of the Dyrk1A gene dosage restored the density of 
Purkinje cells in the cerebellum in TS mice. Representative images of Purkinje cells 
stained with DAPI and PI (A). Means ± S.E.M. of the estimated densities of Purkinje 
cells in each experimental group (B). **: p < 0.01 TS +/+/+ vs. CO +/+; #: p < 0.05 CO 
+/+ vs. CO +/- (n = 32 in B). Significance was determined using ANOVAs and 
Bonferroni’s post hoc test. 
Figure 7. Normalization of the Dyrk1A gene dosage restored the dendritic 
arborization of Purkinje cells in TS mice. Representative images of calbindin 
immunostaining in cerebellar slices of the four groups of animals. The scale bar 

















+/+, CO +/-, TS +/+/+ and TS +/+/- mice. *: p < 0.05 TS +/+/+ vs. CO +/+; ##: p < 0.01 
TS +/+/+ vs. TS +/+/- (n = 32 in B). Significance was determined using ANOVAs and 
Bonferroni’s post hoc tests. 
Figure 8. Normalization of the copy number of the Dyrk1A gene reduced the 
density GABAergic synapse markers and increased the density of glutamatergic 
synapse markers in the cerebellum of TS mice. Representative confocal images of 
sections immunostained for VGAT, VGluT1 and both VGAT and VGluT1. The scale bar 
represents 5 µm (A). Means ± SEM of the percentage of area occupied by VGAT-
positive (B), and VGluT1-positive boutons (C) and the ratio (D) of these areas in the 
cerebellum of TS +/+/+, TS +/+/-, CO +/+ and CO +/- mice. **: p < 0.01, ***: p < 0.001 
TS +/+/+ vs. CO +/+; #: p < 0.05, ##: p < 0.01, ###: p < 0.001 TS +/+/+ vs. TS +/+/- (n 
= 32 in B, C and D). Significance was determined using ANOVAs and Bonferroni’s post 
hoc tests. 
Figure 9. Normalization of the Dyrk1A copy number reduced alterations in the 
walking pattern of TS mice. Means ± S.E.M. of stride length (A), stride width (B), the 
coefficient of variation (C) and the number of strides (D) in TS +/+/+, TS +/+/-, CO +/+ 
and CO +/- mice. Representative images of the walking pattern of an animal from each 
group (E). *: p < 0.05, **: p < 0.01 TS +/+/+ vs. CO +/+; #: p < 0.05, ##: p < 0.01 TS 
+/+/+ vs. TS +/+/- (n = 32 in A, B, C and D). Significance was determined using 
ANOVAs and Bonferroni’s post hoc tests. 
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